You are here: Industry Insights > GSK

News List

GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19 worldpharmanews
April 16, 2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and ...
GSK decides to halt mid-stage feladilimab studies pharmatimes
April 16, 2021
GlaxoSmithKline (GSK) has announced that it will stop enrolling patients into trials evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab.
Low asthma patient adherence shows need for personalised and convenient medicines: GlobalData expresspharma
April 14, 2021
GlobalData has revealed that 80 per cent of asthma patients do not take their medication effectively. The reasons for this poor patient adherence are numerous and can include poor inhaler technique, poor perception, complex regimens and the cost of ...
GSK Consumer Healthcare to incorporate paper bottles into its packaging europeanpharmaceuticalreview
April 07, 2021
To meet its ambitious sustainability targets, GSK Consumer Healthcare has joined the Pulpex paper bottle consortium.
GSK Pharma board approves sale of Vemgal facility to Hetero Labs for Rs 180 crores expresspharma
April 01, 2021
GlaxoSmithKline Pharmaceuticals said its board has approved the sale of its manufacturing facility located at Vemgal in Karnataka to Hetero Labs for a consideration of Rs 180 crores.
GSK agrees to support manufacture of Novavax' COVID-19 vaccine pharmatimes
March 30, 2021
GlaxoSmithKline (GSK) has agreed in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate – NVX-CoV2373 – for use in the UK.
GSK and Vir seek EUA for monoclonal antibody to treat Covid-19 pharmaceutical-technology
March 30, 2021
GlaxoSmithKline (GSK) and Vir Biotechnology have applied to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) for SARS-CoV-2 monoclonal antibody VIR-7831 (GSK4182136) to treat Covid-19.
Lilly, Vir and GSK report positive data from Covid-19 antibody trial pharmaceutical-technology
March 30, 2021
Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline (GSK) have reported topline data from the expanded Phase II BLAZE-4 trial of bamlanivimab (LY-CoV555) co-administered with VIR-7831 (GSK4182136) in low-risk adult patients with mild to ...
Boston Pharmaceuticals signs three-year agreement with GSK pharmaceutical-business-review
March 19, 2021
The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).
GSK launches late-stage study of long-acting antibody for severe asthma pharmatimes
March 18, 2021
GlaxoSmithKline (GSK) has dosed the first patient in a Phase III trial investigating its long-acting anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma (SEA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page